Log in
Enquire now
‌

US Patent 8394826 Dual mechanism inhibitors for the treatment of disease

Patent 8394826 was granted and assigned to Aerie Pharmaceuticals on March, 2013 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Current Assignee
Aerie Pharmaceuticals
Aerie Pharmaceuticals
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
83948260
Patent Inventor Names
Jill Marie Sturdivant0
Mitchell A. deLong0
Susan M. Royalty0
Date of Patent
March 12, 2013
0
Patent Application Number
126949650
Date Filed
January 27, 2010
0
Patent Citations Received
‌
US Patent 12018012 Aryl cyclopropyl-amino-isoquinolinyl amide compounds
0
‌
US Patent 11707460 Ophthalmic compositions
0
‌
US Patent 11891376 Aryl cyclopropyl-amino-isoquinolinyl amide compounds
0
Patent Primary Examiner
‌
D M Seaman
0
Patent abstract

Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 8394826 Dual mechanism inhibitors for the treatment of disease

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.